相关实验视频

Updated: Sep 13, 2025

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

自组装多抗原T细胞杂交剂用于多发性髓瘤的精密免疫疗法

Shannuo Li^1,2, Jiahui Li^1,2, Hasan Al Faruque^1,2

¹Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, 84112, USA.

Advanced healthcare materials

|August 1, 2025

概括

这项研究引入了多抗原TC细胞杂化剂 (MATCH),这是治疗多发性骨髓瘤的新型免疫疗法. 通过模块化地将T细胞与癌细胞接触,MATCH提供了可适应的,针对患者的特定向.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

双特异性T细胞参与剂对多发性骨髓瘤 (MM) 是有前途的,但缺乏适应性.
目前的疗法在针对个性化治疗的灵活性方面面临挑战.

研究的目的:

开发一种基于T细胞的新型模块化免疫疗法平台,用于多功能和患者特异的多发性骨髓瘤向治疗.
创建一个自组装的双特异性T细胞吸引系统,名为MATCH.

主要方法:

开发了Match,这是一个由两个组成部分组成的系统:针对B细胞抗原的Fab'-oligonucleotide合物 (例如BCMA,SLAMF7,CD38) 和抗CD3的Fab'-oligonucleotide合物.
采用了morpholino oligonucleotide杂化方法,在预先定位后在现场组装双特异性复合物.
在患者衍生样本和在人性化小鼠模型中的 in vivo 中验证了 ex vivo 的 MATCH.

主要成果:

MATCH证明了有效的免疫突触形成和强大的抗原特异性细胞毒性对多发性骨髓瘤细胞.
活体研究证实了患者获得的骨髓中显著的瘤细胞枯竭.
在体内研究表明有效的癌症抑制具有有利的药理动力学和分布.

结论:

MATCH是一个灵活且可定制的免疫疗法平台,在多发性骨髓瘤治疗中具有显著的翻译潜力.
MATCH的模块化,自组装性质允许适应性和患者特定的癌症向.

关键词:

B细胞成熟抗原 (BCMA) 是一种用T细胞重定向的免疫疗法.没有药物的宏分子治疗药物.吗啡类寡核化物多发性骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.